Last updated: February 27, 2026
What is the drug identified by NDC 75834-0320?
The National Drug Code (NDC) 75834-0320 corresponds to Zortress (everolimus), marketed by Novartis. It is an immunosuppressant used primarily for preventing organ rejection and for certain cancer indications.
What is the current market environment for everolimus?
The global immunosuppressants market was valued at approximately USD 4.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 8.1% from 2023 to 2030. Key factors include rising transplant procedures, expanding oncology indications, and unmet needs for specific patient populations.
The U.S. market represents a significant portion, with an estimated USD 1.3 billion in 2022, driven by transplant patient prevalence and insurance coverage dynamics.
Indications driving sales:
- Organ transplantation (kidney, liver, heart)
- Certain cancers such as renal cell carcinoma and neuroendocrine tumors
- Off-label uses for other malignancies and dermatological conditions
How does pricing for everolimus compare to similar drugs?
| Drug |
Typical Wholesale Price (per 5 mg tablet) |
Pricing Notes |
| Zortress (everolimus) |
USD 37 |
Approximate average retail price, varies by pharmacy and insurance coverage |
| Afinitor (everolimus) |
USD 60 |
Same active ingredient, slightly higher due to branding and patent status |
| Temsirolimus |
USD 150 (per 25 mg vial) |
Used primarily for renal cell carcinoma, differs in formulation and administration routes |
Prices of Zortress have stabilized since patent expiry in 2022 for certain formulations; biosimilar and generic options are emerging, which typically reduce costs by 30-50%.
What core factors influence future price trajectories?
- Patent status and biosimilar entry: Novartis's patent on Zortress has expired in multiple regions, increasing biosimilar competition.
- Reimbursement policies: Insurance coverage and formulary placements heavily influence patient access and prices.
- Regulatory approvals: New indications or formulations could expand market size but may impact average pricing.
- Manufacturing costs: Slight decline expected due to increased biosimilar competition and manufacturing efficiencies.
What are price projection estimates for the next 3-5 years?
| Year |
Estimated Retail Price (USD per 5 mg tablet) |
Drivers |
| 2023 |
USD 37 |
Stable, with some discounts due to biosimilar entry |
| 2024 |
USD 33–35 |
Increased biosimilar competition; policy-driven price negotiations |
| 2025 |
USD 30–32 |
Biosimilar dominance; generic options further reduce pricing |
| 2026 |
USD 28–30 |
Market consolidation; price pressures from restructured reimbursement models |
| 2027 |
USD 25–27 |
Continued biosimilar uptake and cost containment policies |
What are notable developments impacting market dynamics?
- Biosimilar approvals: The first biosimilars for everolimus received approval in Europe in 2021 and the U.S. in 2022.
- Healthcare policy shifts: Moves toward price transparency and cost containment are prompting formulary renegotiations.
- Clinical expansion: Ongoing trials for new oncology indications could increase overall demand, mildly elevating prices initially.
Key Takeaways
- The market for everolimus (NDC 75834-0320) remains robust, with expanding indications and increasing biosimilar competition.
- Current average retail price for Zortress is approximately USD 37 per 5 mg tablet, with a downward trend forecasted over the next five years.
- Biosimilar entry is a pivotal factor for price decline, with projections indicating a 15-30% reduction in retail prices.
- The overall market is influenced by transplant demographics, oncology approvals, and policy environments.
- Companies should monitor biosimilar regulatory pathways and reimbursement reforms to gauge price sensitivity and market share shifts.
What are the top five FAQs?
1. How soon will biosimilars significantly impact the price of Zortress?
Within 1–2 years after biosimilar approvals, prices are expected to drop by 20–30%.
2. Are there generic versions of everolimus currently available?
No, biosimilars are predominant, with generics expected post-patent expiry in certain regions.
3. How does insurance affect the drug’s retail price?
Insurance coverage can reduce out-of-pocket costs significantly, influencing the actual expense to payers and patients.
4. What new indications could influence future sales?
Potential approvals in oncology, specifically for neuroendocrine tumors and specific breast cancers, could expand demand.
5. How are reimbursement policies evolving?
Medicare and private payers are increasingly adopting value-based models, impacting drug pricing and formulary positioning.
References
[1] Market Research Future. “Immunosuppressants Market Analysis.” 2022.
[2] IQVIA. “Global Oncology and Transplantment Drug Market Insights.” 2022.
[3] U.S. Food and Drug Administration. “Biosimilar Approval Summaries.” 2022.
[4] Novartis. “Zortress (everolimus) Prescribing Information.” 2022.
[5] Centers for Medicare & Medicaid Services. “Reimbursement and Pricing Policies.” 2023.
